combined antiischemic effects thromboxane receptor antagonist SQ tissue-type plasminogen activator thromboxane-receptor antagonist SQ adjuvant therapy thrombolysis antiischemic activity independent thrombolytic activity tissue-type plasminogen activator t-PA antiischemic effects SQ t-PA doses t-PA SQ cardioprotective Anesthetized dogs circumflex coronary artery occlusion minutes reperfusion hours dogs reperfusion dose t-PA reduction plasma fibrinogen combination mg/kg mg/kg/hr SQ minutes initiation ischemia doses t-PA SQ infarct size left ventricular area risk vehicle controls t-PA SQ combination treatment significant reduction infarct size left ventricular area risk doses t-PA SQ infarct size protective effects t-PA SQ peripheral hemodynamic status differences collateral reperfusion blood flow groups Thus SQ efficacy thrombolysis t-PA turn enhance antiischemic activity SQ threshold dose 